Skip to Main Content (Press Enter)

Logo UNIMI
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione

Expertise & Skills
Logo UNIMI

|

Expertise & Skills

unimi.it
  • ×
  • Home
  • Persone
  • Attività
  • Ambiti
  • Strutture
  • Pubblicazioni
  • Terza Missione
  1. Pubblicazioni

The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve pain in a murine model of Fabry–Anderson disease

Articolo
Data di Pubblicazione:
2025
Citazione:
The prokineticin system and glia cells as pharmacological targets to control neuroinflammation and to relieve pain in a murine model of Fabry–Anderson disease / G. Galimberti, S. Franchi, G. Amodeo, P. Romualdi, S. Candeletti, L. Rullo, L. Losapio, V. Onnis, D. Moi, B. Riboldi, G. Magni, S. Ceruti, P. Sacerdote. - In: PAIN. - ISSN 1872-6623. - (2025 Sep 25). [Epub ahead of print] [10.1097/j.pain.0000000000003818]
Abstract:
Neuropathic pain is a major symptom of Fabry-Anderson disease (FD). It develops in childhood, is life-lasting, and resists current therapies; finding new therapeutic strategies is urgently needed. We demonstrate that neuroinflammation control effectively relieves FD pain. We used 2 pharmacological approaches: the microglial inhibitor minocycline and the block of the activity of the chemokine prokineticin-2 with the specific receptor antagonist PC1 (patented compound 1). Ten- and 25-week-old male GLA-/- mice (the FD murine model) were used. These mice were characterized by mechanical allodynia, thermal hyperalgesia, hyposensitivity to cold stimuli, and abdominal pain. Two weeks of treatment with minocycline or PC1 successfully counteracted sensory alterations. A significant inflammatory state, characterized by high levels of prokineticin-2 and proinflammatory cytokines, was present in the FD gut. The sciatic nerve showed initial severe neuroinflammation that attenuated over time. In dorsal root ganglia, neuroinflammation was severe and persistent with prokineticin-2, proinflammatory cytokines, ionized calcium-binding adapter molecule 1, and glial fibrillary acidic protein overexpression; histone demethylases KDM6A and B were also upregulated. We highlighted neuroinflammation in the spinal cord that increased over time. Treatment with minocycline or PC1 significantly counteracted inflammation and neuroinflammation, reducing prokineticin-2 and proinflammatory cytokines levels and increasing anti-inflammatory factor PPARγ expression. Both treatments prevented the onset of micro- and astrogliosis in the spinal cord. We underline the role of neuroinflammation and microglia in FD pain and suggest that treatments that control the activity of the prokineticin system, glial activation, and the production of proinflammatory cytokines and increase anti-inflammatory mediators have a therapeutic effect on pain in FD.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Neuroinflammation; Pain; Prokineticin system; Glial cells; Minocycline; Fabry disease; GLA-/- mice
Elenco autori:
G. Galimberti, S. Franchi, G. Amodeo, P. Romualdi, S. Candeletti, L. Rullo, L. Losapio, V. Onnis, D. Moi, B. Riboldi, G. Magni, S. Ceruti, P. Sacerdote
Autori di Ateneo:
CERUTI STEFANIA MARIA ( autore )
GALIMBERTI GIULIA ( autore )
RIBOLDI BENEDETTA ( autore )
SACERDOTE PAOLA GIUSEPPINA ( autore )
Link alla scheda completa:
https://air.unimi.it/handle/2434/1186415
Link al Full Text:
https://air.unimi.it/retrieve/handle/2434/1186415/3151446/Pain_Fabry_2025.pdf
Progetto:
Pharmacological block of the prokineticin system and of microglia activation to treat pain and mood disorders in Fabry-Anderson disease
  • Aree Di Ricerca

Aree Di Ricerca

Settori


Settore BIOS-11/A - Farmacologia
  • Informazioni
  • Assistenza
  • Accessibilità
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Progettato da Cineca | 25.11.5.0